PRESS RELEASE
For Immediate Release
First patient enrolled in GOG-3132/BEHOLD-Ovarian01 phase 3 study evaluating Mocertatug Rezetecan, a novel B7-H4–targeted ADC, in platinum-resistant ovarian cancer
Philadelphia, PA, USA, July 27, 2026 – The GOG Foundation, Inc. is proud to announce the enrollment of the first patient in GOG-3132/BEHOLD-Ovarian01 (NCT07286266), a global Phase 3 clinical trial titled A Randomized, Open-label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants with Platinum-resistant Ovarian Cancer. The study is sponsored by GSK and conducted in collaboration with The GOG Foundation, Inc.
Dr. Floor Backes, Principal Investigator of GOG-3132/BEHOLD-Ovarian01 and gynecologic oncologist at The Ohio State University Comprehensive Cancer Center, stated, “We are pleased to announce the enrollment of the first patient in BEHOLD-Ovarian01, an important milestone in the clinical development of mocertatug rezetecan. Building on the encouraging activity observed in the phase 1 BEHOLD-1 study, this Phase 3 trial will help determine whether B7-H4–targeted therapy can improve outcomes for patients with platinum-resistant ovarian cancer, an area of significant unmet medical need.”
Click here to read the full press release.